We recently traveled to Pittsburgh, Pennsylvania, for a State of the Science Summit™ on Lung Cancer. At the meeting, faculty from the University of Pittsburgh Medical Center and Fox Chase Cancer Center discussed how chemoimmunotherapy has changed the standard of care in stage IV nonsquamous non–small cell lung cancer (NSCLC), highlighted how up-front immunotherapy has become a pivotal part of treatment in squamous NSCLC, and explained how immunotherapy’s success in lung cancer has set the stage for future research.
In addition, faculty examined PD-L1 and tumor mutational burden as biomarkers of immunotherapy response in NSCLC, and provided insight into overcoming acquired resistance to targeted therapy.
Interested in attending an upcoming OncLive®
State of the Science Summit™ in your area? Register today